Figure 7.
Effects of different inhibitors on IL-1β-, IL-18- and IL-33-induced survival enhancement of human eosinophils. Eosinophils (5×105 cells) were pre-treated with inhibitors for 30 min followed by incubation with or without (a) IL-1β, (b) IL-18 and (c) IL-33 (50 ng/ml) in the presence of inhibitors for a further 48 h. Percent viability of eosinophils was assessed by the TACS Annexin V-FITC assay using flow cytometry and are expressed as the arithmetic mean±SEM of three independent experiments. *P<0.05, **P<0.01 when compared between groups denoted by the horizontal lines. AG, AG490; BAY, BAY11-7082; Ctrl, medium control; FITC, fluorescein isothiocyanate; IL, interleukin; LY, LY294002; U, U0126; SB, SB203580; SP, SP600125.